

Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-Sep-2018
 Document Type: USP Monographs
 DocId: GUID-9D6ECEC6-E1F6-46D6-9A11-0542C31E5C50_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M54076_04_01
 DOI Ref: 18g4z

© 2025 USPC
 Do not distribute

Add the following:

▲Milrinone Lactate Injection

DEFINITION

Milrinone Lactate Injection is a sterile aqueous solution of Milrinone and a suitable osmolality-adjusting substance in Water for Injection, prepared with the aid of Lactic Acid. It contains NLT 90.0% and NMT 110.0% of the labeled amount of milrinone ($C_{12}H_9N_3O$).

IDENTIFICATION

- **A.** The retention time of the milrinone peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV absorption spectrum of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the corresponding peak of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: Dissolve 3.3 g of dibasic potassium phosphate in 1 L of [water](#) and add 3 mL of [triethylamine](#). Adjust with [phosphoric acid](#) to a pH of 7.5.

Mobile phase: [Acetonitrile](#) and *Buffer* (20:80)

Standard solution: 0.05 mg/mL of [USP Milrinone RS](#) in *Mobile phase*. Sonication may be necessary for complete dissolution.

Sample solution: Nominally equivalent to 0.05 mg/mL of milrinone prepared from a volume of Injection suitably diluted with *Mobile phase*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 220 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 25-cm; 5-μm packing L7

Flow rate: 1 mL/min

Injection volume: 20 μL

Run time: NLT 1.7 times the retention time of milrinone

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of milrinone ($C_{12}H_9N_3O$) in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of milrinone from the *Sample solution*

r_S = peak response of milrinone from the *Standard solution*

C_S = concentration of [USP Milrinone RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of milrinone in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

Buffer and **Mobile phase:** Prepare as directed in the Assay.

System suitability solution: 0.5 μg/mL each of [USP Milrinone RS](#) and [USP Milrinone Related Compound A RS](#) in *Mobile phase*

Standard solution: 0.5 μg/mL of [USP Milrinone RS](#) in *Mobile phase*

Sensitivity solution: 0.1 µg/mL of [USP Milrinone RS](#) in *Mobile phase* from *Standard solution*

Sample solution: Nominally 500 µg/mL of milrinone from a volume of Injection in *Mobile phase*

Chromatographic system: Proceed as directed in the Assay, except for the *Run times*.

Run times

Standard solution: NLT 1.7 times the retention time of milrinone

Sample solution: NLT 4 times the retention time of milrinone

System suitability

Samples: *System suitability solution*, *Standard solution*, and *Sensitivity solution*

Suitability requirements

Resolution: NLT 5.0 between milrinone and milrinone related compound A, *System suitability solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 20, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100 \quad \blacktriangle (\text{ERR 1-Sep-2018})$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of milrinone from the *Standard solution*

C_S = concentration of [USP Milrinone RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of milrinone in the *Sample solution* (µg/mL)

$\blacktriangle$ (ERR 1-Sep-2018)

Acceptance criteria: See [Table 1](#). Disregard peaks below 0.01%.

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Milrinone related compound A ^a	0.6	—
Milrinone	1.0	—
Any unspecified degradation product	—	0.20
Total impurities ^b	—	0.5

^a Process-related impurity; 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carboxamide.

^b Total impurities include both process-related and degradation products.

SPECIFIC TESTS

• CONTENT OF LACTIC ACID

Mobile phase: [Water](#) adjusted with [phosphoric acid](#) to a pH of 2.1

Standard solution: 0.2 mg/mL of [USP Sodium Lactate RS](#) in *Mobile phase*

Sample solution: Nominally equivalent to 0.2 mg/mL of milrinone prepared as follows. Transfer a suitable volume of Injection into a suitable volumetric flask and add about 8% of the flask volume of 1.0 N [sodium hydroxide](#) solution. Shake well and keep for 10 min. Neutralize with an equal amount of 1.0 N [sulfuric acid](#) and dilute with *Mobile phase* to volume.

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector UV 210 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Flow rate: 1 mL/min

Injection volume: 20 µL

Run times